论文部分内容阅读
用四种实验方法对丹参新成分β-(3,4-二羟基苯基)乳酸(简称丹参素),丹参-781(简称781),原儿茶醛(简称 PCAD)及潘生丁等药进行研究,从而确定了丹参治冠心病的主要有效成分为丹参素。该成分已能合成,并已进行临床试用。1.丹参素能显著延长小鼠耐缺氧时间,其作用次于氯丙嗪,但显著较丹参酮Ⅱ A 磺酸钠强。PCAD 抗缺氧无效。2.对于脑垂体后叶素引起的大鼠缺血性心电变化,丹参素有显著保护作用,潘生丁、781或 PCAD 也有部分的保护作用。
Four kinds of experimental methods were used to study the new components of salvia miltiorrhiza, such as Danshensu, Salvia miltiorrhiza-781, protocatechuic aldehyde (PCAD) and dipyridamole , To determine the main effective component of Salvia treatment of coronary heart disease is danshensu. This ingredient has been synthesized and has been clinically tested. Danshensu can significantly prolong the hypoxia tolerance in mice, its effect is inferior to chlorpromazine, but significantly stronger than tanshinone Ⅱ A sulfonate. PCAD anti-hypoxia is invalid. 2. For pituitrin-induced ischemic ECG changes in rats, Danshensu have a significant protective effect, dipyridamole, 781 or PCAD also have some of the protective effect.